Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 203 of 5804
-
Could the time of day you get immunotherapy boost its power against melanoma?
Disease control Not yet recruitingMelanoma remains a common cancer with rising incidence, and despite significant improvements with immune checkpoint inhibitors (ICIs), clinical outcomes remain heterogeneous. Retrospective analyses across multiple tumor types, including melanoma, suggest that earlier daytime admi…
Phase: PHASE4 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental drug targets Hard-to-Treat neuroendocrine cancers
Disease control Not yet recruitingThis study will enroll patients with central lab confirmed NCAM (CD56 IHC) positive metastatic neuroendocrine neoplasms that have progressed after standard of care treatment. CTX-471 to be administered as an intravenous (IV) infusion at either 0.3 mg/kg or 0.6 mg/kg every 2 weeks…
Phase: PHASE2 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for aggressive prostate cancer: carboplatin combo tested in phase 3 trial
Disease control Not yet recruitingThe current standard of patients with de novo metastatic hormone sensitive prostate cancer (mHSPC) is to offer androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI). In addition, upfront 6 cycles of docetaxel, if patient is eligible, and prostate rad…
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Electric zaps to the gut could tame diabetes and fatty liver
Disease control Not yet recruitingThis study is designed to evaluate the efficacy, safety, and mechanisms of pulsENDO procedure in patients with T2DM and its effect on MASLD.
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New injection combo takes aim at tough skin cancers
Disease control Recruiting nowOpen-label, single-arm, multicenter study in patients with locally advanced, histologically confirmed Cutaneous Squamous Cell Carcinoma (LacSCC) amenable to intratumoral injection, who have progressed on or are intolerant to Immune Checkpoint Inhibitor (ICI). The primary objectiv…
Phase: PHASE2 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could a new drug beat the current standard for septic shock?
Disease control Not yet recruitingDespite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determi…
Phase: PHASE4 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for rare ovarian cancer: drug shrinks tumors after immunotherapy fails
Disease control Not yet recruitingOvarian clear cell carcinoma (OCCC) is a relatively rare but highly malignant epithelial ovarian cancer, accounting for 5%-10% of all ovarian cancers. The incidence of this tumor has significant racial disparity, with the highest incidence in Asians, accounting for 25% of ovarian…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 26, 2026 16:50 UTC
-
Heart-Safe chemo? trial aims to shield patients from lifelong damage
Disease control Not yet recruitingThis trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care R-CHOP or pola-R-CHP treatment regiments. The names of…
Phase: PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug takes aim at hard-to-treat neuroendocrine prostate cancer
Disease control Not yet recruitingThis is a phase 2, open-label, single-arm study of sacituzumab tirumotecan in neuroendocrine prostate cancer (NEPC) with progression after platinum-based chemotherapy.
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug velzatinib tested for Hard-to-Treat stomach and intestinal tumors
Disease control Not yet recruitingThe goal of this study is to evaluate the study drug velzatinib (GSK6042981 / IDRX-42) to see whether velzatinib can shrink or control tumors and is safe and tolerated in Japan participants with gastrointestinal tumors (GIST) who progressed or were intolerant to standard therapie…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Two-Drug cocktail aims to shrink Hard-to-Treat esophageal and stomach tumors
Disease control Not yet recruitingThis is a single-arm, multi-center phase II study to evaluate the efficacy and safety of sacituzumab tirumotecan (Sac-TMT/SKB264) combined with tagitanlimab (KL-A167) as 2nd line therapy for recurrent or metastatic esophageal squamous cell carcinoma (ESCC) or gastric/gastroesopha…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Can a simple ultrasound improve rattlesnake bite care?
Diagnosis Not yet recruitingEarly identification of tissue injury from a rattlesnake bite is critical to prevent complications and reduce health care costs. Given the limitations of clinical assessment, there is a need to develop a more objective reproducible, anatomically detailed diagnostic tool for to ac…
Sponsor: University of Arizona • Aim: Diagnosis
Last updated Jul 19, 2026 00:00 UTC
-
New drug cocktail aims to shrink recurrent ovarian tumors
Disease control Not yet recruitingThis is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.
Phase: PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can a dissolving tablet improve recovery after a common stroke?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if Y-6 sublingual tablets work to improve functional outcomes in patients with acute perforating artery infarction. It will also learn about the safety of Y-6 sublingual tablets. The main questions it aims to answer are: Does Y-6 subl…
Phase: PHASE2, PHASE3 • Sponsor: Neurodawn Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New hope for richter transformation: targeted drug combo heads to phase III
Disease control Not yet recruitingThis phase III trial compares the effect of adding pirtobrutinib to the usual treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) to R-CHOP alone for the treatment of Richter transformation, which is when chronic lymphocytic leukemia or sm…
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for kids with Crohn's: drug trial targets remission
Disease control Recruiting nowThis phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New hope for NMOSD patients: drug aims to slash relapse rate
Disease control Not yet recruitingThe primary objective of this study is to confirm the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of ravulizumab in the treatment of Chinese adults with anti-aquaporin-4 (AQP4) antibody (Ab) + neuromyelitis optica spectrum disorder (NMOSD).
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo aims to tame HPV throat cancer with fewer side effects
Disease control Not yet recruitingThis research study is testing whether a new study drug (called ATRN-119) is safe and effective when combined with a single, highly targeted dose of radiation therapy (called stereotactic body radiation therapy or SBRT) to treat early-stage throat cancer that is caused by HPV. T…
Phase: PHASE1, PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug aims to cut heart risk for patients with high lp(a) after heart attack
Disease control Not yet recruitingCTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in participants with elevated Lp(a) and recent acute coronary…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Laser zaps brain tumor, then immunotherapy fights back: new hope for glioblastoma?
Disease control Not yet recruitingThis study will assess the therapeutic efficacy of the combination of Laser Interstitial Thermal Therapy (LiTT) with adjuvant cemiplimab compared to the therapeutic efficacy of the combination of LiTT with physician's choice of adjuvant chemotherapy in patients with recurrent gli…
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC